We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy.
- Authors
Dudley, Beth; Karloski, Eve; Monzon, Federico A.; Singhi, Aatur D.; Lincoln, Stephen E.; Bahary, Nathan; Brand, Randall E.
- Abstract
<bold>Background: </bold>Approximately 10% of pancreatic adenocarcinoma (PC) cases are attributed to hereditary causes. Individuals with PC and a personal history of another cancer associated with hereditary breast and ovarian cancer (HBOC) or Lynch syndrome (LS) may be more likely to carry germline mutations.<bold>Methods: </bold>Participants with PC and a history of cancer were selected from a pancreatic disease registry. Of 1296 individuals with PC, 149 had a relevant history of cancer. If banked DNA was available, a multigene panel was performed for individuals who had not 1) previously had a mutation identified through clinical testing or 2) undergone clinical multigene panel testing with no mutations detected.<bold>Results: </bold>Twenty-two of 124 individuals with PC and another HBOC- or LS-related cancer who underwent genetic testing had a mutation identified in a PC susceptibility gene (18%). If prostate cancer is excluded, the mutation prevalence increased to 23% (21/93). Mutation carriers were more likely to have more than 1 previous cancer diagnosis (P = .001), to have had clinical genetic testing (P = .001), and to meet National Comprehensive Cancer Network (NCCN) genetic testing criteria (P < .001). Approximately 23% of mutation carriers did not meet NCCN HBOC or LS testing guidelines based on their personal cancer history and reported cancer history in first-degree relatives.<bold>Conclusion: </bold>At least 18% of individuals with PC and a personal history of other HBOC- or LS-related cancers carry mutations in a PC susceptibility gene based on our data, suggesting that criteria for genetic testing in individuals with PC should include consideration of previous cancer history. Cancer 2018;124:1691-700. © 2018 American Cancer Society.
- Subjects
ADENOCARCINOMA; OVARIAN cancer; DNA; PROSTATE cancer; CLINICAL trials; GENETICS
- Publication
Cancer (0008543X), 2018, Vol 124, Issue 8, p1691
- ISSN
0008-543X
- Publication type
journal article
- DOI
10.1002/cncr.31242